The reason for this stems from the differences in both response to FTIs and differences in ferroptosis defense systems where STK11/KEAP1-mutant lung cancer harbors very effective anti-ferroptosis systems through SLC7A11/GPX4, AIFM2, and AKR1C. This evidence concerns the gene AIFM2 and lung cancer.